comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-11 11:45:58 - browse：539

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Heat waves linked to early deliveries, preterm births in new study

hotspot

WSS

First Opinion Podcast: What happens when kids become caregivers?

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

FDA poised to publish guidelines for clinical trial diversity

Liver decline slowed by off

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Akili, maker of video game for ADHD, to be acquired for 34 million

knowledge

comprehensive

hotspot

Hollywood unions extend contract negotiations for actors

Stigma and the return of syphilis

New air purifier tech could be key to improving indoor air quality

Fentanyl is making it harder to start addiction treatment

BioMarin wins approval for gene therapy to treat hemophilia A

Latest bird flu infection made farmworker sicker than earlier cases

At least 13 dead in Texas as scorching temps continue

Citing H5N1 threat, CDC urges peak flu monitoring this summer

DIEP, the 'gold standard' of breast reconstruction, is under threat

UnitedHealth argues against case alleging wrongful AI care denials

hotspot

Addressing health care workers' trauma can help fight burnout

H5N1 virus can be tracked in retail milk, scientists say

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Investigation reveals sickle cell patients pressured into sterilizations

David Sabatini, ex

entertainment

Wikipedia

hotspot

entertainment